RCT: Final analysis of 3 vs. 6 months of adjuvant Oxaliplatin and Fluoropyrimidine-based therapy in patients with Stage III colon cancer.

Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial – Journal of Clinical Oncology

Commentaries on Twitter

https://twitter.com/drkpavithran/status/1522370036072996865